These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

923 related articles for article (PubMed ID: 27828943)

  • 21. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3K Isoform Immunotherapy for Solid Tumours.
    Scott J; Rees L; Gallimore A; Lauder SN
    Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant immune checkpoint blockade triggers persistent and systemic T
    Blomberg OS; Kos K; Spagnuolo L; Isaeva OI; Garner H; Wellenstein MD; Bakker N; Duits DEM; Kersten K; Klarenbeek S; Hau CS; Kaldenbach D; Raeven EAM; Vrijland K; Kok M; de Visser KE
    Oncoimmunology; 2023; 12(1):2201147. PubMed ID: 37089449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy-induced tumour secretomes promote resistance and tumour progression.
    Obenauf AC; Zou Y; Ji AL; Vanharanta S; Shu W; Shi H; Kong X; Bosenberg MC; Wiesner T; Rosen N; Lo RS; Massagué J
    Nature; 2015 Apr; 520(7547):368-72. PubMed ID: 25807485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3Kγ Activates Integrin α
    Foubert P; Kaneda MM; Varner JA
    Cancer Immunol Res; 2017 Nov; 5(11):957-968. PubMed ID: 28963139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
    Xin G; Chen Y; Topchyan P; Kasmani MY; Burns R; Volberding PJ; Wu X; Cohn A; Chen Y; Lin CW; Ho PC; Silverstein R; Dwinell MB; Cui W
    Cancer Immunol Res; 2021 Apr; 9(4):454-469. PubMed ID: 33579728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
    Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
    Front Immunol; 2021; 12():754196. PubMed ID: 35003065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma.
    Schlenker R; Schwalie PC; Dettling S; Huesser T; Irmisch A; Mariani M; Martínez Gómez JM; Ribeiro A; Limani F; Herter S; Yángüez E; Hoves S; Somandin J; Siebourg-Polster J; Kam-Thong T; de Matos IG; Umana P; Dummer R; Levesque MP; Bacac M
    Med; 2024 Jul; 5(7):759-779.e7. PubMed ID: 38593812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-32γ potentiates tumor immunity in melanoma.
    Gruber T; Kremenovic M; Sadozai H; Rombini N; Baeriswyl L; Maibach F; Modlin RL; Gilliet M; von Werdt D; Hunger RE; Seyed Jafari SM; Parisi G; Abril-Rodriguez G; Ribas A; Schenk M
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32841222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
    Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF
    Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma.
    Lelliott EJ; Mangiola S; Ramsbottom KM; Zethoven M; Lim L; Lau PKH; Oliver AJ; Martelotto LG; Kirby L; Martin C; Patel RP; Slater A; Cullinane C; Papenfuss AT; Haynes NM; McArthur GA; Oliaro J; Sheppard KE
    Cancer Immunol Res; 2021 Feb; 9(2):136-146. PubMed ID: 33303574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3Kγ is a molecular switch that controls immune suppression.
    Kaneda MM; Messer KS; Ralainirina N; Li H; Leem CJ; Gorjestani S; Woo G; Nguyen AV; Figueiredo CC; Foubert P; Schmid MC; Pink M; Winkler DG; Rausch M; Palombella VJ; Kutok J; McGovern K; Frazer KA; Wu X; Karin M; Sasik R; Cohen EE; Varner JA
    Nature; 2016 Nov; 539(7629):437-442. PubMed ID: 27642729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
    Chakraborty B; Byemerwa J; Shepherd J; Haines CN; Baldi R; Gong W; Liu W; Mukherjee D; Artham S; Lim F; Bae Y; Brueckner O; Tavares K; Wardell SE; Hanks BA; Perou CM; Chang CY; McDonnell DP
    J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34637400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
    Li J; Kaneda MM; Ma J; Li M; Shepard RM; Patel K; Koga T; Sarver A; Furnari F; Xu B; Dhawan S; Ning J; Zhu H; Wu A; You G; Jiang T; Venteicher AS; Rich JN; Glass CK; Varner JA; Chen CC
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33846242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.
    Canè S; Van Snick J; Uyttenhove C; Pilotte L; Van den Eynde BJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis.
    Tauriello DVF; Palomo-Ponce S; Stork D; Berenguer-Llergo A; Badia-Ramentol J; Iglesias M; Sevillano M; Ibiza S; Cañellas A; Hernando-Momblona X; Byrom D; Matarin JA; Calon A; Rivas EI; Nebreda AR; Riera A; Attolini CS; Batlle E
    Nature; 2018 Feb; 554(7693):538-543. PubMed ID: 29443964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.